日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers

2025年泌尿系统晚期肿瘤共识会议(AUC3):肾细胞癌和泌尿系统肿瘤治疗的专家共识

McKay, Rana R; Pal, Sumanta; Xie, Wanling; Aggen, David; Albiges, Laurence; Apolo, Andrea; Atkins, Michael B; Bangs, Rick; Beckermann, Kathryn E; Bellmunt, Joaquim; Berg, Stephanie A; Bilen, Mehmet A; Braun, David; Carlo, Maria I; Efstathiou, Jason; Galsky, Matthew; Grivas, Petros; Gupta, Shilpa; Haas, Naomi; Hakimi, A Ari; Hammers, Hans; Heng, Daniel Y C; Hirsch, Michelle; Iyer, Gopakumar; Jonasch, Eric; Koshkin, Vadim S; Kryvenko, Oleksandr; Lewis, Bryan; Li, Roger; Matin, Surena; Maughan, Benjamin; McDermott, David F; McGregor, Bradley; Meeks, Joshua; Milowsky, Matthew; Motzer, Robert; Necchi, Andrea; Petrylak, Dan; Porten, Sima; Powles, Thomas; Rini, Brian; Shuch, Brian; Siefker-Radtke, Arlene; Sonpavde, Guru; Sridhar, S Srikala; Suarez, Cristina; Tang, Chad; Tripathi, Abhishek; Van Der Heijden, Michiel S; Voss, Martin; Xu, Wenxin; Zhang, Tian; Rosenberg, Jonathan; Choueiri, Toni K

Partitioned overall survival: comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma

分区总生存期:CheckMate 9ER 研究中对晚期肾细胞癌一线治疗方案(纳武利尤单抗联合卡博替尼与舒尼替尼)4 年生存状态的综合分析

Viray, Hollis; M Mantia, Charlene; Jegede, Opeyemi A; Atkins, Michael B; Rosenblatt, Lisa; Choueiri, Toni K; McDermott, David F; Regan, Meredith M

Phase 1 LITESPARK-001 study of belzutifan in participants with advanced solid tumors: Results of the glioblastoma expansion cohort

贝祖替凡治疗晚期实体瘤患者的 I 期 LITESPARK-001 研究:胶质母细胞瘤扩展队列的结果

Strowd, Roy E; de la Fuente, Macarena; Bauer, Todd M; Papadopoulos, Kyriakos P; Chen, Ke; Perini, Rodolfo F; Liu, Yanfang; McDermott, David F

Tumor-Intrinsic and Microenvironmental Determinants of Impaired Antitumor Immunity in Chromophobe Renal Cell Carcinoma

嗜铬细胞肾细胞癌中肿瘤内在和微环境因素导致抗肿瘤免疫受损

Labaki, Chris; Saad, Eddy; Madsen, Katrine N; Hobeika, Charbel; Bi, Kevin; Alchoueiry, Michel; Camp, Sabrina; Hou, Yue; Bakouny, Ziad; Matar, Sayed; El Ahmar, Nourhan; Nyman, Jackson; Zhang, Long; Priolo, Carmen; Rout, Rishabh; Daou, Melissa; Khabibullin, Damir; Salem, Samer; Schindler, Nicholas; Saliby, Renée Maria; Meli, Kevin; Wells, J Connor; Pimenta, Erica; Takemura, Kosuke; Park, Jihye; Eid, Marc; Semaan, Karl; Fu, Jingxin; Denize, Thomas; El Hajj Chehade, Razane; Machaalani, Marc; Nawfal, Rashad; Khatoun, Wassim Daoud; Saleh, Mustafa; El Masri, Jad; Haddad, Nina Rossa; Xu, Wenxin; McGregor, Bradley A; Hirsch, Michelle S; Xie, Wanling; Heng, Daniel Y C; McDermott, David F; Signoretti, Sabina; Van Allen, Eliezer M; Shukla, Sachet A; Choueiri, Toni K; Henske, Elizabeth P; Braun, David A

Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047

RELATIVITY-047 研究分析了接受纳武利尤单抗单药治疗或联合瑞拉利单抗治疗的晚期黑色素瘤患者的无治疗生存期。

Regan, Meredith M; Ascierto, Paolo A MD; Lipson, Evan J; Palaia, Jennell; Moshyk, Andriy; Selvan, Abraham; Lao, Christopher D; Atkins, Michael B MD; McDermott, David F; Potluri, Ravi; Ranjan, Sandip; Bilthare, Sandeep; Long, Georgina V; Stephen Hodi, F; Tawbi, Hussein; Schadendorf, Dirk

Nemvaleukin alfa monotherapy in patients with advanced melanoma and renal cell carcinoma: results from the phase 1/2 non-randomized ARTISTRY-1 trial

Nemvaleukin alfa 单药治疗晚期黑色素瘤和肾细胞癌患者:来自 ARTISTRY-1 1/2 期非随机试验的结果

Calvo, Emiliano; Boni, Valentina; Dumas, Olivier; Shin, Sang Joon; Rosen, Seth D; Chaudhry, Arvind; Debruyne, Philip R; He, Xiaomin; Vaishampayan, Ulka N; McDermott, David F

Role of high-dose interleukin-2 for melanoma in the age of cellular therapy

在细胞疗法时代,高剂量白细胞介素-2在黑色素瘤治疗中的作用

Buchbinder, Elizabeth; Lotze, Michael T; Margolin, Kim A; Amaria, Rodabe; Sarnaik, Amod; Seery, Virginia; Eroglu, Zeynep; Khaddour, Karam; Betof Warner, Allison; Kluger, Harriet M; Sznol, Mario; Atkins, Michael B; Mcdermott, David F; Silk, Ann W

How can we increase the value of clinical trials with immunotherapy?

如何提高免疫疗法临床试验的价值?

Atkins, Michael B MD; Mcdermott, David F

Long-Term Performance of Prognostic Models for Advanced Renal Cell Carcinoma in the Era of Improved Survival With Immune Checkpoint Inhibitors

免疫检查点抑制剂提高晚期肾细胞癌生存率时代,预后模型的长期表现

Mantia, Charlene M; Jegede, Opeyemi A; McDermott, David F; Heng, Daniel Y C; Xie, Wanling; Choueiri, Toni K; Atkins, Michael B; Regan, Meredith M

Updated overall survival in patients with prior checkpoint inhibitor therapy in the phase III TIVO-3 study

III期TIVO-3研究中既往接受过免疫检查点抑制剂治疗的患者的总生存期更新

Zugman, Miguel; McDermott, David F; Escudier, Bernard J; Hutson, Thomas E; Porta, Camillo; Verzoni, Elena; Atkins, Michael B; Rini, Brian; Pal, Sumanta K